JOURNAL DESCRIPTION
The Medical Radiology and Radiation Safety journal ISSN 1024-6177 was founded in January 1956 (before December 30, 1993 it was entitled Medical Radiology, ISSN 0025-8334). In 2018, the journal received Online ISSN: 2618-9615 and was registered as an electronic online publication in Roskomnadzor on March 29, 2018. It publishes original research articles which cover questions of radiobiology, radiation medicine, radiation safety, radiation therapy, nuclear medicine and scientific reviews. In general the journal has more than 30 headings and it is of interest for specialists working in thefields of medicine¸ radiation biology, epidemiology, medical physics and technology. Since July 01, 2008 the journal has been published by State Research Center - Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency. The founder from 1956 to the present time is the Ministry of Health of the Russian Federation, and from 2008 to the present time is the Federal Medical Biological Agency.
Members of the editorial board are scientists specializing in the field of radiation biology and medicine, radiation protection, radiation epidemiology, radiation oncology, radiation diagnostics and therapy, nuclear medicine and medical physics. The editorial board consists of academicians (members of the Russian Academy of Science (RAS)), the full member of Academy of Medical Sciences of the Republic of Armenia, corresponding members of the RAS, Doctors of Medicine, professor, candidates and doctors of biological, physical mathematics and engineering sciences. The editorial board is constantly replenished by experts who work in the CIS and foreign countries.
Six issues of the journal are published per year, the volume is 13.5 conventional printed sheets, 88 printer’s sheets, 1.000 copies. The journal has an identical full-text electronic version, which, simultaneously with the printed version and color drawings, is posted on the sites of the Scientific Electronic Library (SEL) and the journal's website. The journal is distributed through the Rospechat Agency under the contract № 7407 of June 16, 2006, through individual buyers and commercial structures. The publication of articles is free.
The journal is included in the List of Russian Reviewed Scientific Journals of the Higher Attestation Commission. Since 2008 the journal has been available on the Internet and indexed in the RISC database which is placed on Web of Science. Since February 2nd, 2018, the journal "Medical Radiology and Radiation Safety" has been indexed in the SCOPUS abstract and citation database.
Brief electronic versions of the Journal have been publicly available since 2005 on the website of the Medical Radiology and Radiation Safety Journal: http://www.medradiol.ru. Since 2011, all issues of the journal as a whole are publicly available, and since 2016 - full-text versions of scientific articles. Since 2005, subscribers can purchase full versions of other articles of any issue only through the National Electronic Library. The editor of the Medical Radiology and Radiation Safety Journal in accordance with the National Electronic Library agreement has been providing the Library with all its production since 2005 until now.
The main working language of the journal is Russian, an additional language is English, which is used to write titles of articles, information about authors, annotations, key words, a list of literature.
Since 2017 the journal Medical Radiology and Radiation Safety has switched to digital identification of publications, assigning to each article the identifier of the digital object (DOI), which greatly accelerated the search for the location of the article on the Internet. In future it is planned to publish the English-language version of the journal Medical Radiology and Radiation Safety for its development. In order to obtain information about the publication activity of the journal in March 2015, a counter of readers' references to the materials posted on the site from 2005 to the present which is placed on the journal's website. During 2015 - 2016 years on average there were no more than 100-170 handlings per day. Publication of a number of articles, as well as electronic versions of profile monographs and collections in the public domain, dramatically increased the number of handlings to the journal's website to 500 - 800 per day, and the total number of visits to the site at the end of 2017 was more than 230.000.
The two-year impact factor of RISC, according to data for 2017, was 0.439, taking into account citation from all sources - 0.570, and the five-year impact factor of RISC - 0.352.
Issues journals
Medical Radiology and Radiation Safety. 2024. Vol. 69. № 4
DOI:10.33266/1024-6177-2024-69-4-81-87
Е.А. Rasskazova 1, A.D. Zikiryakhodzhaev 1-3
Results of Treatment of Patients with Stage I‒Ii Breast Cancer after Subcutaneous/Skin-Preserving Mastectomies with Reconstruction with/without Radiation Therapy
1 P.A. Hertsen Moscow Oncology Research Institute, Moscow, Russia
2 I.M. Sechenov First Moscow State Medical University, Moscow, Russia
3 People’s Friendship University of Russia, Moscow, Russia
Contact person: E.A. Rasskazova, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
Abstract
Purpos: To study the oncological results and features of complications in patients with breast cancer in stages I‒II after subcutaneous/skin-preserving mastectomies with reconstruction with/without radiation therapy.
Material and methods: From 2013 to 2022, 984 breast cancer patients underwent 1020 subcutaneous/skin-preserving mastectomies with simultaneous one- or two-stage reconstruction at the Herzen Moscow Medical Research Institute.
Subcutaneous mastectomy with reconstruction was performed in 617 (60.5 %), skin-preserving mastectomy in 403 (39.5 %) cases.
Reconstruction with the patient’s own tissues was performed in 5.7 %, expanders/implants in 94.3 % of patients.
Results: The recurrence rate of breast cancer was 41 (4.2±0.6 %), the frequency of distant metastases was diagnosed in 53 (5.4±0.7 %) in the studied group of patients.
Complications were diagnosed in 241 (24.5 %) patients.
Recurrence in the group with radiation therapy was 2.6±0.6 (OR 0.98, CI 1.52‒3.48, 95 %), without radiation therapy 5.9 % (OR 2.13, CI 0.92‒5.18, 95 %) regardless of the stage of breast cancer (criterion T > 2, p ˂ 0,05).
Capsular contracture (CC) of the III‒IV degree was diagnosed in 9.4 % of the analyzed group of patients.
Capsular contracture of the III‒IV degree worsens the aesthetic result of breast reconstruction, as well as reduces the quality of life of patients. With simultaneous two–stage reconstruction, the risk of developing CC was 4.2 % (after LT 4.7 %, without LT 3.6 %), with one-stage reconstruction, the risk of developing CC 11.2 % (after LT 15.8 %, without LT 4 %).
In the study group of patients, the effect of LT on the risk of CC was 12.6 %, without LT 3.7 % (p < 0.05), the difference is statistically significant.
In our study, the recurrence of breast cancer at the edge of R1 was 6.8±2.5 %, at R0 – 3±0.6 % (p > 0.05).
When analyzing the age and risk of recurrence, we did not identify an age dependence, before 40 years the probability of recurrence was 4.3±1 %, after 40 years – 3.3±0.7 % (criterion T = 0.44, p > 0.05).
A statistically significant difference in our study was revealed, except for radiation therapy, during NAPHT, thus, in the group with NAPHT, the recurrence was 2.4± 0.8 %, without NAPHT – 4.6±0.7 % (criterion T = 2.16, p ˂ 0.05).
When performing a simultaneous two-stage reconstruction of a patient with the inclusion of radiation therapy (LT), the risk of skin protrusion was 18 %, without radiation therapy – 8.3 %.
Capsular contracture (CC) of the III‒IV degree was diagnosed in 9.4 % of the analyzed group of patients.
Capsular contracture of the III‒IV degree worsens the aesthetic result of breast reconstruction, as well as reduces the quality of life of patients. With simultaneous two–stage reconstruction, the risk of developing CC was 4.2 % (after LT 4.7 %, without LT 3.6 %), with one-stage reconstruction, the risk of developing CC 11.2 % (after LT 15.8 %, without LT 4 %).
In the study group of patients, the effect of LT on the risk of CC was 12.6 %, without LT 3.7 % (p < 0.05), the difference is statistically significant.
Keywords: breast cancer, recurrence, skin-preserving mastectomies, subcutaneous mastectomies, radiation therapy, reconstruction, implants, protrusion, capsular contracture
For citation: Rasskazova ЕА, Zikiryakhodzhaev AD. Results of Treatment of Patients with Stage I‒Ii Breast Cancer after Subcutaneous/Skin-Preserving Mastectomies with Reconstruction with/without Radiation Therapy. Medical Radiology and Radiation Safety. 2024;69(4):81–87. (In Russian). DOI:10.33266/1024-6177-2024-69-4-81-87
References
1. Каприн А.Д., Старинский В.В., Шахзадова А.О. Состояние онкологической помощи населению России в 2022 году. М.: МНИОИ им. П.А. Герцена, 2022. 239 с. [Kaprin A.D., Starinskiy V.V., Shahzadova A.O. Sostoyanie Onkologicheskoy Pomoshchi Naseleniyu Rossii v 2022 godu = The State of Cancer Care for the Population of Russia in 2022. Moscow, MNIOI im. P.A.Gertsena Publ., 2022. 239 p. (In Russ.)].
2. Демидов С.М., Демидов Д.А., Сазонов С.В., Чуракова Е.И. Иммуногистохимические характеристики рака молочной железы, увеличивающие риск локального рецидива после органосохраняющего лечения // Опухоли женской репродуктивной системы. 2018. Т.15, №3. С. 10–14 [Demidov S.M., Demidov D.A., Sazonov S.V., Churakova E.I. Immunohistochemical Characteristics of Breast Cancer that Increase the Risk Of Local Recurrence after Breast-Conserving Treatment. Opukholi Zhenskoy Reproduktivnoy Sistemy = Tumors of the Female Reproductive System. 2018;15(3):10–4 (In Russ.)].
3. Дружков М.О., Гатауллин И.Г., Дружков О.Б. Динамика иммунофенотипа рака молочной железы от первичной опухоли к локальному рецидиву // Онкохирургия. 2011. Т. 3, № 2. С. 26. [Druzhkov M.O., Gataullin I.G., Druzhkov O.B. Dynamics of the Immunophenotype of Breast Cancer from the Primary Tumor to Local Relapse. Onkokhirurgiya = Oncosurgery. 2011;3;2:26 (In Russ.)].
4. Малыгин С.Е., Малыгин Е.Н., Петерсон С.Б. Местные и региональные рецидивы после мастэктомии с одномоментной реконструкцией при раке молочной железы // Вестник Российского государственного медицинского университета. 2013. № 4. С. 24-27 [Malygin S.E., Malygin E.N., Peterson S.B. Local and Regional Relapses after Mastectomy with Simultaneous Reconstruction for Breast Cancer. Vestnik Rossiyskogo Gosudarstvennogo Meditsinskogo Universiteta = Bulletin of the Russian State Medical University. 2013;4:24-27 (In Russ.)].
5. Wu ZY, Han HH, Han J, Kim HJ, Lee J, Chung IY, Kim J, Lee S, Eom JS, Kim SB, Gong G, Kim HH, Son BH, Ahn SH, Ko B. Impact of Local Breast Cancer Recurrence on Reconstructed Breast in Nipple-Sparing Mastectomy with Immediate Reconstruction. J Plast Reconstr Aesthet Surg. 2022 Aug;75(8):2535-2541. doi: 10.1016/j.bjps.2021.05.030.
6. Vuong B, Darbinian J, Savitz A, Odele P, Perry LM, Sandhu L, Habel LA, Kuehner G. Breast Cancer Recurrence by Subtype in a Diverse, Contemporary Cohort of Young Women. J Am Coll Surg. 2023 Jul 1;237(1):13-23. doi: 10.1097/XCS.0000000000000714.
7. Christopher AN, Morris MP, Jia H, Patel V, Broach RB, Serletti JM, Fosnot J. Managing Locoregional Breast Cancer Recurrence after Autologous Free Flap Reconstruction: A Retrospective Review of 2,734 Procedures. J Plast Reconstr Aesthet Surg. 2022 Feb;75(2):562-570. doi: 10.1016/j.bjps.2021.09.078.
8. Woodward S, Willis A, Lazar M, Berger AC, Tsangaris T. Nipple-Sparing Mastectomy: a Review of Outcomes at a Single Institution. Breast J. 2020 Nov;26(11):2183-2187. doi: 10.1111/tbj.14088.
9. Adra J, Lundstedt D, Killander F, Holmberg E, Haghanegi M, Kjellén E, Karlsson P, Alkner S. Distribution of Locoregional Breast Cancer Recurrence in Relation to Postoperative Radiation Fields and Biological Subtypes. Int J Radiat Oncol Biol Phys. 2019 Oct 1;105(2):285-295. doi: 10.1016/j.ijrobp.2019.06.013.
10. Wang J, Luo J, Jin K, Wang X, Yang Z, Ma J, Mei X, Wang X, Zhou Z, Yu X, Chen X, Guo X. Biological Subtype Predicts Locoregional Recurrence after Postmastectomy Radiotherapy in Chinese Breast Cancer Patients. Cancer Med. 2020 Apr;9(7):2427-2434. doi: 10.1002/cam4.2904.
11. Chen SY, Sun GY, Tang Y, Jing H, Song YW, Jin J, Liu YP, Zhao XR, Song YC, Chen B, Qi SN, Tang Y, Lu NN, Li N, Fang H, Li YX, Wang SL. Timing of Postmastectomy Radiotherapy Following Adjuvant Chemotherapy for High-Risk Breast Cancer: a Post Hoc Analysis of a Randomised Controlled Clinical Trial. Eur J Cancer. 2022 Oct;174:153-164. doi: 10.1016/j.ejca.2022.07.023.
12. Jagsi R, Barlow WE, Woodward WA, Connolly E, Mahtani R, Shumway D, Speers C, Stecklein SR, Zeidan Y, Zhang H, Sharma P, Pusztai L, Hortobagyi GN, Kalinsky K. Radiotherapy Use and Incidence of Locoregional Recurrence in Patients With Favorable-Risk, Node-Positive Breast Cancer Enrolled in the SWOG S1007 Trial. JAMA Oncol. 2023 Aug 1;9(8):1083-1089. doi: 10.1001/jamaoncol.2023.1984.
13. Kim D, Kim JH, Kim IA, Chang JH, Shin KH. Impact of Postmastectomy Radiation Therapy on Breast Cancer Patients According to Pathologic Nodal Status after Modern Neoadjuvant Chemotherapy. Cancer Res Treat. 2023 Apr;55(2):592-602. doi: 10.4143/crt.2022.998.
14. Brett JO, Mayer EL. New Developments in Systemic Management for High-Risk Early-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer. Curr Treat Options Oncol. 2023 Jun;24(6):594-610. doi: 10.1007/s11864-023-01082-3.
15. Chen BF, Tsai YF, Lien PJ, Lin YS, Feng CJ, Chen YJ, Cheng HF, Tseng LM, Huang CC. Clinical Characteristics and Treatment Outcomes of Invasive Ductal and Lobular Carcinoma: Analyses of 54,832 Taiwan Cancer Registry Index Cases. Breast Cancer Res Treat. 2023 Oct;201(3):547-560. doi: 10.1007/s10549-023-07044-5.
16. Рак молочной железы: Клинические рекомендации. М.: Минздрав России, 2021-2023. 94 с. [Rak Molochnoj Zhelezy. Klinicheskie Rekomendatsii = Breast Cancer: Clinical Recommendations. Moscow, Minzdrav Rossii Publ., 2021-2023. 94 p. (In Russ.)].
17. Eichler C, Schulz C, Thangarajah F, Malter W, Warm M, Brunnert K. A Retrospective Head-to-head Comparison Between TiLoop Bra/TiMesh® and Seragyn® in 320 Cases of Reconstructive Breast Surgery. Anticancer Res. 2019 May;39(5):2599-2605. doi: 10.21873/anticanres.13383. PMID: 31092458.
18. Kim JH, Chun YS, Park HK, Kim SE, Kim YW, Cheon YW. Inframammary Fold Incision Can Reduce Skin Flap Necrosis in Immediate Breast Reconstruction With Implant and Conjoined Fascial Flap. Ann Plast Surg. 2020 Nov;85(5):488-494. doi: 10.1097/SAP.0000000000002393. PMID: 32332387
19. Vaccari S, Klinger F, Sciretta AP, Di Giuli R, Bandi V, Veronesi A, Catania B, Klinger M, Vinci V. Implant-Based Breast Reconstruction: Impact of Body Mass Index on Postoperative Complications and Aesthetic Results: A 5-Year, Single-Center Study. Aesthet Surg J. 2023, 16 Now; 43(12): NP1063-NP1070. doi: 10.1093/asj/ sjad289. PMID: 37658866.
20. Zheng C, Liu J, Wen Y, Lin S, Han H, Xu C. A Systematic Review and Meta-Analysis of Postmastectomy Radiation Therapy on Prepectoral Versus Subpectoral Breast Reconstruction. Front Surg. 2023 Jan 9;9:1019950. doi: 10.3389/fsurg.2022.1019950. PMID: 36700017; PMCID: PMC9869385.
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Rasskszova A.E. ‒ idea and design of the trial; Zikiryakhodzhaev A.D. – reviewing.
Article received: 20.03.2024. Accepted for publication: 25.04.2024.
Medical Radiology and Radiation Safety. 2024. Vol. 69. № 4
DOI:10.33266/1024-6177-2024-69-4-88-93
R.V. Zelchan, A.A. Medvedeva, O.D. Bragina, A.N. Rуbina,
E.A. Dudnikova, V.V. Visotskaya, V.E. Goldberg, V.I. Chernov
Spect/Ct with a New Radiopharmaceutical “99mtc, Octreotide” in Diagnosis and Evaluation of the Effectiveness of Treatment of Neuroendocrine Tumor of the Lung (Clinical Case)
Cancer Research Institute, Tomsk National Research Medical Center, Tomsk, Russia
Contact person: R.V. Zelchan, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
Purpose: to demonstrate the possibilities of using SPECT/CT with the new radiopharmaceutical “99mTс, Octreotide” in the diagnosis, assessment of the extent of the process and monitoring of the effectiveness of treatment of neuroendocrine lung tumors.
Material and methods: the presented clinical case examines the medical history of a patient with verified neuroendocrine cancer of the right lung with extensive local spread and the presence of distant lymph node metastases (retroperitoneal lymph nodes) and hematogenous dissemination to bones (ribs and vertebrae). During the initial diagnosis and at the stages of chemotherapy treatment, along with traditional methods of instrumental and laboratory examination, the patient underwent “99mTc, Octreotide” SPECT/CT. The results of the study were assessed visually and using the SUV (standardized accumulation level). When interpreting the results of “99mTc, Octreotide” SPECT/CT with special attention was paid to the dynamics of the SUV indicator at control points for assessing the effectiveness of chemotherapy
treatment.
Results: The results obtained demonstrated the possibility of effective use of “99mTc, Octreotide” SPECT/CT at the stage of primary diagnosis of a neuroendocrine tumor. The data obtained not only confirmed the presence of a malignant tumor of a neuroendocrine nature in the patient, but also made it possible to correctly stage the tumor process, since additional pathological foci were identified in distant lymph nodes and bones. In addition, the use of “99mTc, Octreotide” SPECT/CT during control examinations at the stages of chemotherapy treatment of a patient made it possible to supplement the significance of diagnostic information obtained using traditional research methods and to more reliably assess the effectiveness of the therapy. Already at the first control examination, pronounced positive dynamics were observed after 3 courses of chemotherapy in the form of a decrease in the number of foci of pathological accumulation of “99mTc, Octreotide” and a decrease in the intensity of its inclusion in the remaining areas of the tumor lesion. Also, during further examinations at control points, the opposite – negative dynamics was noted in the form of the appearance of new foci of pathological accumulation of “99mTc, Octreotide”.
Conclusion: The presented experience in the clinical use of “99mTc, Octreotide” SPECT/CT demonstrated the effectiveness and ease of use of this method in patients with neuroendocrine tumors. In addition, the results obtained today make it possible to successfully use the new domestic radiopharmaceutical for the diagnosis of neuroendocrine tumors.
Keywords: radiopharmaceutical, neuroendocrine tumor of the lung, 99mTc-octreotide, SPECT/CT
For citation: Zelchan RV, Medvedeva AA, Bragina OD, Rуbina AN, Dudnikova EA, Visotskaya VV, Goldberg VE, Chernov VI. Spect/Ct with a New Radiopharmaceutical “99mtc, Octreotide” in Diagnosis and Evaluation of the Effectiveness of Treatment of Neuroendocrine Tumor of the Lung (Clinical Case). Medical Radiology and Radiation Safety. 2024;69(4):88–93. (In Russian). DOI:10.33266/1024-6177-2024-69-4-88-93
References
1. Dasari A., Shen C., Halperin D., Zhao B., Zhou S., Xu Y., et al. Trends in the Incidence., Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol. 2017;3;10:1335–42. doi: http://dx.doi.org/10.1001/jamaon-col.2017.0589.
2. Reubi J.C., Waser B. Concomitant Expression of Several Peptide Receptors in Neuroendocrine Tumors: Molecular Basis for in Vivo Multi Receptor Tumor Targeting. Eur J Nucl Med Mol Imaging. 2003;30;5:781–793. doi: http://dx.doi.org/10.1007/s00259-003-1184-3.
3. Körner M. Specific Biology of Neuroendocrine Tumors: Peptide Receptors as Molecular Targets. Best Pract Res Clin Endocrinol Metab. 2016;30;1:19–31. doi: http://dx.doi.org/10.1016/j.beem.2016.01.001.
4. Deroose C.M., Hindié E., Kebebew E., Goichot B., Pacak K., Taïeb D., et al. Molecular Imaging of Gastroenteropancreatic Neuroendocrine Tumors: Current Status and Future Directions. J Nucl Med. 2016;57;12:1949–1956. doi: http://dx.doi.org/10.2967/ jnumed.116.179234.
5. Чойнзонов Е.Л., Чижевская С.Ю., Мусабаева Л.И., Фролова И.Г., Авдеев С.В., Синилкин И.Г., Зельчан Р.В., Суркова П.В., Кушнер А.В. Результаты комбинированного лечения больных раком гортани и гортаноглотки // Сибирский онкологический журнал. 2012. №1. С. 5-9. [Choynzonov E.L., Chizhevskaya S.Yu., Musabayeva L.I., Frolova I.G., Avdeyev S.V., Sinilkin I.G., Zel`chan R.V., Surkova P.V., Kushner A.V. Results of Combined Treatment of Patients with Cancer of the Larynx and Hypopharynx. Sibirskiy Onkologicheskiy Zhurnal = Siberian Journal of Oncology. 2012;1:5-9 (In Russ.)].
6. Chernov V.I., Sinilkin I.G., Zelchan R.V., Medvedeva A.A., Lyapunov A.Yu., Bragina O.D., Varlamova N.V., Skuridin V.S. Experimental Study of 99mTc-Aluminum Oxide Use for Sentinel Lymph Nodes Detection. AIP Conference Proceedings, 2016. P. 020012.
7. Тицкая А.А., Чернов В.И., Слонимская Е.М., Синилкин И.Г., Зельчан Р.В. Маммосцинтиграфия с 99mТс-МИБИ в диагностике рака молочной железы // Сибирский медицинский журнал. Г. Томск. 2010. Т. 25. № 4-1. С. 92-95. [Titskaya A.A., Chernov V.I., Slonimskaya E.M., Sinilkin I.G., Zel`chan R.V. Mammoscintigraphy with 99mTc-MIBI in the Diagnosis of Breast Cancer. Sibirskiy Meditsinskiy Zhurnal = The Siberian Medical Journal. Tomsk. 2010;25;4-1:92-95 (In Russ.)].
8. Bragina O., Chernov V., Zelchan R., Medvedeva A., Schulga A., Vorobyeva A., Orlova A., Deyev S., Tolmachev V., Konovalova E., Garbukov E., Tashireva L., Sorensen J. Phase I Trial of 99mTc-;HE3-G3., a DARPin-Based Probe for Imaging of HER2 Expression in Breast Cancer. Journal of Nuclear Medicine. 2022;63;4:528-535.
9. Delle Fave G., Kwekkeboom DJ., Van Cutsem E., Rindi G., Kos-Kudla B., Knigge U., et al. Barcelona Consensus Conference Participants. ENETS Consensus Guidelines for the Management of Patients with Gastroduodenal Neoplasms. Neuroendocrinology. 2012;95;2:74–87. doi: http://dx.doi.org/10.1159/000335595.
10. Koyasu S., Shimizu Y., Nakamoto Y. 68Ga-DOTATOC PET/CT for Diagnosing Neuroendocrine Tumors. Gan To Kagaku Ryoho. 2022;49;8:821-825.
11. Чернов В.И., Брагина О.Д., Зельчан Р.В., Медведева А.А., Синилкин И.Г., Ларькина М.С., Стасюк Е.С., Нестеров Е.А., Скуридин В.С. Меченые аналоги соматостатина в тераностике нейроэндокринных опухолей // Медицинская радиология и радиационная безопасность. 2017. Т.62. №3. С. 42-49. [Chernov V.I., Bragina O.D., Zel`chan
R.V., Medvedeva A.A., Sinilkin I.G., Lar`kina M.S., Stasyuk E.S., Nesterov E.A., Skuridin V.S. Labeled Somatostatin Analogues in Theranostics of Neuroendocrine Tumors. Meditsinskaya Radiologiya i Radiatsionnaya Bezopasnost = Medical Radiology and Radiation Safety. 2017;62;3:42-49 (In Russ.)].
12. Briganti V., Cuccurullo V., Di Stasio GD., Mansi L. Gamma Emitters in Pancreatic Endocrine Tumors Imaging in the PET Era: Is there a Clinical Space for 99mTc-peptides? Curr Radiopharm. 2019;12;2:156-170. doi: 10.2174/1874471012666190301122524.
13. Briganti V., Cuccurullo V., Berti V., Di Stasio GD., Linguanti F., Mungai F., Mansi L. 99mTc-EDDA/HYNIC-TOC is a New Opportunity in Neuroendocrine Tumors of the Lung ;and in other Malignant and Benign Pulmonary Diseases. Curr Radiopharm. 2020;13;3:166-176. doi: 10.2174/1874471013666191230143610.
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The work was carried out with the financial support of the Ministry of Education and Science of Russia. State contract 14.N08.11.0166 for the implementation of applied scientific research and experimental developments for state needs.
Contribution. Zelchan R.V.: collection and analysis of literary material, development of concept and design, analysis and interpretation of data, writing text; Chernov V.I.: development of concept and design, scientific editing of the text, final approval for publication of the manuscript; Rybina A.N., Medvedeva A.A., Bragina O.D.: development of the concept of research, development research design, data analysis; Dudnikova, V.V. Vysotskaya, V.E. Goldberg: collection of material, data analysis.
Article received: 20.03.2024. Accepted for publication: 25.04.2024.
Medical Radiology and Radiation Safety. 2024. Vol. 69. № 3
DOI:10.33266/1024-6177-2024-69-3-5-12
A.A. Rastorgueva1, T.A. Astrelina1, V.A. Brunchukov1, I.V. Kobzeva1,
Yu.B. Suchkova1, V.A. Nikitina1, S.V. Lishchuk1, E.A. Dubova1, K.A. Pavlov1,
T.F. Malivanova1, D.Yu. Usupzhanova1, O.G. Mikhadarkina1, A.D. Kobzev2,
V.I. Bulygina2, A.S. Samoilov1
Evaluation of the Effectiveness of The Use of Decellularized Human Amniotic Membrane
in Combination with Cell Therapy for Local Radiation Injuries
1 A.I. Burnazyan Federal Medical Biophysical Center, Moscow, Russia
2 M.I. Sechenov University, Moscow, Russia
Contact person: T.A. Astrelina, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
Аbstract
Cell therapy is a promising direction in medicine, which can significantly improve the results of treatment of various diseases, including local radiation injuries (LRI). The purpose of the study was to compare the results of using decellularized human amniotic membrane isolated and together with lyophilisates of conditioned media of MSCs from the human gingival mucosa and MSCs from human placental tissue and their effect on tissue regeneration in LRI.
Material and methods: The study included 42 laboratory animals (white male rats of the Wistar line), randomly divided into 6 groups: K – control group without therapy, on the 21st day after irradiation, groups using: Am+LD – application of lyophilisate of the conditioned medium of MSCs of the human gingival mucosa (LD) under the decellularized amniotic membrane, Am+LP – application of lyophilisate of the conditioned medium of MSCs of human placental tissue (LP) under the decellularized amniotic membrane, Am – application of the decellularized amniotic membrane, AmCl – application of the decellularized amniotic membrane with medical glue BF-6, Kl – application medical glue BF-6. Modeling of LRI in animals was carried out on an LNK-268 X-ray unit at a dose of 110 Gy and observed until the 112th day after irradiation, monitoring of the ulcerative surface of the skin and the course of the inflammatory process of LRI was carried out with calculation of the area of the total changed skin in the ImageTool software. Planimetric and histological analyzes were performed.
Results: It was demonstrated that, when compared with the control, the use of decellularized amniotic membrane in LRI on days 77 and 112 after irradiation increased the healing rate by 4.6 and 18 times, respectively; decellularized amniotic membrane with lyophilisate of placental MSC conditioned medium increased the rate of wound healing by 13.5 and 27 times, respectively; and a dellularized amniotic membrane with lyophilisate of MSCs from the human gingival mucosa to 100 % healing. Healing of the ulcer surface area of the LRI in 83.5 % of animals in the Am group demonstrated the effectiveness of using isolated decellularized amniotic membrane even in the absence of human MSC lyophilisates. At the same time, healing of the ulcer surface area of the LRI in the AmCl group was 20 % of cases, where the decellularized amniotic membrane was fixed with BF-6 medical glue, which was less effective compared
to other groups.
Conclusion: The proposed combined use of decellularized amniotic membrane with lyophilisates of the conditioned medium of mesenchymal stromal cells (MSCs) of the placenta and mucous tissue of the human gums and the isolated use of decellularized amniotic membrane led to complete epithelization of the ulcer surface, a pronounced favorable course of grade IIIb–IV LRI in laboratory animals and a reduction in healing time , the absence of local or systemic complications can be considered as a promising method of conservative treatment for LRI of the skin and a new therapeutic approach in the treatment of non-healing and chronic wounds.
Keywords: local radiation injuries, human decellularized amniotic membrane, cell therapy, mesenchymal stromal cells, conditioned medium, rats
For citation: Rastorgueva AA, Astrelina TA, Brunchukov VA, Kobzeva IV, Suchkova YuB, Nikitina VA, Lishchuk SV, Dubova EA, Pavlov KA, Malivanova TF, Usupzhanova DYu, Mikhadarkina OG, Kobzev AD, Bulygina VI, Samoilov AS. Evaluation of the Effectiveness of The Use of Decellularized Human Amniotic Membrane in Combination with Cell Therapy for Local Radiation Injuries. Medical Radiology and Radiation Safety. 2024;69(3):5–12. (In Russian). DOI:10.33266/1024-6177-2024-69-3-5-12
References
1. Diagnosis, Treatment of Local Radiation Injuries and Their Long-Term Consequences. Federal Clinical Guidelines. FKR FMBA of Russia 2.6.7. Moscow, 2015.
2. Brunchukov V.A., Astrelina T.A., Nikitina V.A., et al. The Use of Placental Mesenchymal Stromal Cells for Local Radiation Lesions of the Skin. Genes and Cells. 2019;14:41 (In Russ.).
3. Rastorgueva A.A., Astrelina T.A., Brunchukov V.A., et al. The Effectiveness of the Use of Rat and Human MSCs and Their Conditioned Media for Local Radiation Injuries in a Laboratory Animal Model. Genes and cells. 2022;3;17:194 (In Russ.).
4. Brunchukov V., Astrelina T., Nikitina V., et al. Experimental Treatment of Radiation Skin Lesions with Mesenchymal Stem Cells and Their Conditioned Media. Medical Radiology and Radiation Safety. 2020;65;1:5-12. doi:10.12737/1024-6177-2020-65-1-5-12.
5. Rastorgueva A.A., Astrelina T.A., Brunchukov V.A., et al. Application of Cellular Technologies in the Treatment of Local Radiation Injuries. Abstract book IRPA15. 15 th International Congress of the International Radiation Protection Association. January 18-22, 2021 in Seoul, Korea. Korea, Р. 328-333.
6. Kobzeva I.V., Astrelina T.A., Brunchukov V.A., et al. Transplantation of Decellularized Human Amniotic Membrane for Local Radiation Injuries. Medical Radiology and Radiation Safety. 2022;67;6:5-11 (In Russ.).
7. Chen P., Lu M., Wang T., et al. Human Amniotic Membrane as a Delivery Vehicle for Stem Cell-Based Therapies. Life Sci. 2021;1;272:119157. doi: 10.1016/j.lfs.2021.119157.
8. Leal-Marin S., Kern T., Hofmann N., et al. Human Amniotic Membrane: A Review on Tissue Engineering, Application, and Storage. J. Biomed Mater Res. B. Appl. Biomater. 2021;109;8:1198-1215. doi: 10.1002/jbm.b.34782.
9. Panteleyev A.A., Sytina E.V., Chaban E.A., Paltsev M.A. Use of Human Fetal Amniotic Membrane in Skin Bioengineering. Molecular Medicine. 2016;14;5:49-54 (In Russ.).
10. Jahanafrooz Z., Bakhshandeh B., Behnam Abdollahi S., et al. Human Amniotic Membrane as a Multifunctional Biomaterial: Recent Advances and Applications // J. Biomater Appl. 2023. V.37. No. 8. P. 1341-1354. doi: 10.1177/08853282221137609.
11. Samoilov A.S., Astrelina T.A., Brumberg V.A., Brunchukov V.A., Kobzeva I.V., Malivanova T.F., Ostashkin A.S. A Method for Obtaining an Acellular Matrix of the Amniotic Membrane for Subsequent Reconstruction of Tissue Defects. Patent for Invention No. 2751353RU dated 07/13/2021] (In Russ.).
12. Kakabadze Z., Chakhunashvili D., Gogilashvili K., Ediberidze K., Chakhunashvili K., Kalandarishvili K., Karalashvili L. Bone Marrow Stem Cell and Decellularized Human Amniotic Membrane for the Treatment of Nonhealing Wound after Radiation Therapy. Exp. Clin. Transplant. 2019;17;1:92-98. doi: 10.6002/ect.MESOT2018.O29.
13. Asanuma H., Meldrum D.R., Meldrum K.K. Therapeutic Applications of Mesenchymal Stem Cells to Repair Kidney Injury. J. Urol. 2010;184;1:26-33.
14. Walter M.N., Wright K.T., Fuller H.R., MacNeil S., Johnson W.E. Mesenchymal Stem Cell-Conditioned Medium Accelerates Skin Wound Healing: an in Vitro Study of Fibroblast and Keratinocyte Scratch Assays. Exp. Cell. Res. 2010;316;7:1271-1281.
15. Kwon H.M., Hur S.M., Park K.Y., et al. Multiple Paracrine Factors Secreted by Mesenchymal Stem Cells Contribute to Angiogenesis. Vascul. Pharmacol. 2014;63;1:19-28.
16. Koob T.J., Lim J.J., Massee M., Zabek N., Denoziere G. Properties of Dehydrated Human Amnion/Chorion Composite Grafts: Implications for Wound Repair and Soft Tissue Regeneration. J. Biomed Mater Res. B Appl. Biomater. 2014;102;6:1353-1362.
17. Guo Q., Lu X., Xue Y., et al. A New Candidate Substrate for Cell-Matrix Adhesion Study: the Acellular Human Amniotic Matrix. J. Biomed Biotechnol. 2012;2012:306083.
18. Mrugala A., Sui A., Plummer M., et al. Amniotic Membrane Is a Potential Regenerative Option for Chronic Non-Healing Wounds: a Report of Five Cases Receiving Dehydrated Human Amnion/Chorion Membrane Allograft. Int. Wound J. 2016;13;4:485-492.
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The study was carried out with financial support from the Federal Target Program “Ensuring Nuclear and Radiation Safety for 2016–2020 and for the period until 2035”.
Contribution. Article was prepared with equal participation of the authors.
Article received: 20.01.2024. Accepted for publication: 27.02.2024.
Medical Radiology and Radiation Safety. 2024. Vol. 69. № 4
DOI:10.33266/1024-6177-2024-69-4-94-96
I.O. Tomashevsky, O.S. Kornikova
The Importance of the SPECT/СT in the Diagnosis
of Asymptomatic Myocardial Ischemia for a Specific Patient
Central Clinical Hospital RZD-Medicine, Moscow, Russia
Contact person: I.O. Tomashevsky, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
Purpose: To demonstrate a clinical observation in which the diagnosis of ischemic heart disease with vasospastic coronary microvascular dysfunction was established mainly using 99mTc-MIBI SPECT/CT.
Material and methods: In patient G.D.S., 39 years old by profession of an electric locomotive driver, who did not present any health complaints, oblique ST segment depression was registered during Holter monitoring on ECG. The following methods were used to establish the diagnosis: echocardiography, X-ray computed tomography (CT) to assess coronary artery calcinosis, single-photon emission computed tomography (SPECT) with 99mTc-technetril to assess myocardial perfusion and contractile function on hybrid SPECT/CT system SymbiaT16 (Siemens), coronary angiography (CAG).
Results: Only at examination on hybrid tomograph at rest and during physical activity (bicycle ergometer 125 W ‒
5 minutes), sequentially applying in one diagnostic procedure two studies (CT and SPECT with 99mTc-MIBI) 26 study parameters were obtained (at CT ‒ 4 parameters evaluating coronary artery calcinosis, at SPECT ‒ 11 parameters of perfusion and 11 parameters of myocardial function). The absence of coronary artery calcinosis was revealed (which was confirmed by CAG), and the study at rest and during exercise revealed a decrease in perfusion (hence myocardial blood flow) in the apical-lateral (16-th segment); apex (17), apical-anterior (13), anterior-medial (7), anterolateral middle (12); irreversibility of perfusion defect, total and ischemic perfusion deficit.
Conclusion: A clinical observation is demonstrated in which, only the use of hybrid SPECT/CT system allowed to establish the absence of coronary artery calcinosis and the decrease of perfusion (hence myocardial blood flow), irreversibility of perfusion defect, total and ischemic perfusion deficit (all listed indices had penultimate moderately pronounced degree).
Keywords: SPECT/CT, ischemic heart disease, asymptomatic state
For citation: Tomashevsky IO, Kornikova OS. The Importance of the SPECT/СT in the Diagnosis of Asymptomatic Myocardial Ischemia for a Specific Patient. Medical Radiology and Radiation Safety. 2024;69(4):94–96. (In Russian). DOI:10.33266/1024-6177-2024-69-4-94-96
References
1. Khachirova E.A. State of myocardial perfusion and diastolic function in patients with stenocardiaand unchanged coronary arteries (according to hybrid single-photon emission computed tomography with 99mTc-technetrile. Diss.Ph.D. of Medical Sciences. Moscow 2020.
2. A.A. Ansheles V.B. Sergienko. Nuclear cardiology.Publishing house FSBI«National Medical Research Center of Cardiology»Ministry of Health of Russia.Moscow: 2021. ‒ С.75‒125.
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. I.O. Tomashevsky took part in the development of the concept, design, theoretical basis, modification of research methods. O. Kornikova took part in the collection and analysis of literary material, statistical data processing, writing and scientific editing of the text.
Article received: 20.03.2024. Accepted for publication: 25.04.2024.
Medical Radiology and Radiation Safety. 2024. Vol. 69. № 3
DOI:10.33266/1024-6177-2024-69-3-13-18
A.A. Osipov1, A.K. Chigasova1, 2, 3, E.I. Yashkina1, 2, M.A. Ignatov1, 2,
N.Yu. Vorobyеva1, 2, A.N. Osipov1, 2
Link Between Cellular Senescence and Changes in The Number and Size of Phosphorylated Histone H2ax Foci in Irradiated Human Fibroblasts
1 N.N. Semenov Federal Research Center for Chemical Physics, Moscow, Russia
2 A.I. Burnazyan Federal Medical Biophysical Center, Moscow, Russia
3 Institute of Biochemical Physics, Moscow, Russia
Contact person: N.Yu. Vorobyеva, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
Purpose: To analyze the relationship between cellular aging and changes in the number and size of phosphorylated histone H2AX (γH2AX) foci in human fibroblasts and their descendants (up to 15 passages) after exposure to low and high doses of X-ray radiation.
Material and methods: The work was performed on a culture of human skin fibroblasts. Cells were irradiated in the exponential growth phase on an X-ray biological unit RUB RUST-M1 (Russia), equipped with two X-ray emitters, at a dose rate of 40 mGy/min (dose 100 mGy) or 850 mGy/min (doses 2000 and 5000 mGy) and temperature 4˚C. Immunocytochemical staining was used to assess the number and size of γH2AX foci and the proportion of proliferating cells using antibodies to γH2AX and Ki67 (a cell proliferation marker protein), respectively. To assess cellular senescence, the proportion of cells positive for senescence-associated β-galactosidase (CA-β-gal(+)) was analyzed. Statistical and mathematical analysis of the obtained data was carried out using the statistical software package Statistica 8.0 (StatSoft).
Results: The studies showed that irradiation of cultured human fibroblasts at a low dose (100 mGy) does not lead to statistically significant changes in the number and size of γH2AX foci, as well as the proportion of non-proliferating and senescent cells in the progenies of irradiated cells up to the 15th passage after irradiation. The phenomenon of aging-associated persistence of an increased number and size of γH2AX foci in passages of cells irradiated at a dose of 5000 mGy was discovered. Mathematical analysis of the relationship between changes in the proportion of CA-β-gal(+) cells, the number and size of γH2AX foci in populations of irradiated cells indicates that radiation-induced cellular aging is more associated with the size, rather than the number, of γH2AX foci.
Keywords: fibroblasts, X-ray radiation, γH2AX, senescence, proliferation, late radiation-induced effects
For citation: Osipov AA, Chigasova AK, Yashkina EI, Ignatov MA, Vorobyеva NYu, Osipov AN. Link Between Cellular Senescence and Changes in The Number and Size of Phosphorylated Histone H2ax Foci in Irradiated Human Fibroblasts. Medical Radiology and Radiation Safety. 2024;69(3):13–18. (In Russian). DOI:10.33266/1024-6177-2024-69-3-13-18
References
1. Dabin J, Mori M, Polo SE. The DNA Damage Response in the Chromatin Context: a Coordinated Process. Curr Opin Cell Biol. 2023;82:102176. doi: 10.1016/j.ceb.2023.102176.
2. Georgoulis A, Vorgias C, Chrousos G, Rogakou E. Genome Instability and γH2AX. International Journal of Molecular Sciences. 2017;18(9). doi: 10.3390/ijms18091979.
3. Shibata A, Jeggo PA. DNA Double-Strand Break Repair in a Cellular Context. Clin Oncol (R Coll Radiol). 2014;26(5):243-9. doi: 10.1016/j.clon.2014.02.004.
4. Rothkamm K, Barnard S, Moquet J, Ellender M, Rana Z, Burdak-Rothkamm S. DNA Damage Foci: Meaning and Significance. Environ Mol Mutagen. 2015;56(6):491-504. doi: 10.1002/em.21944.
5. Biswas H, Makinwa Y, Zou Y. Novel Cellular Functions of ATR for Therapeutic Targeting: Embryogenesis to Tumorigenesis. International Journal of Molecular Sciences. 2023;24(14). doi: 10.3390/ijms241411684.
6. Bushmanov A, Vorobyeva N, Molodtsova D, Osipov AN. Utilization of DNA Double-Strand Breaks for Biodosimetry of Ionizing Radiation Exposure. Environmental Advances. 2022;8. doi: 10.1016/j.envadv.2022.100207.
7. Merighi A, Gionchiglia N, Granato A, Lossi L. The Phosphorylated Form of the Histone H2AX (γH2AX) in the Brain from Embryonic Life to Old Age. Molecules. 2021;26(23). doi: 10.3390/molecules26237198.
8. Palla V-V, Karaolanis G, Katafigiotis I, Anastasiou I, Patapis P, Dimitroulis D, et al. gamma-H2AX: Can It Be Established as a Classical Cancer Prognostic Factor? Tumor Biology. 2017;39(3). doi: 10.1177/1010428317695931.
9. Marcotte R, Lacelle C, Wang E. Senescent Fibroblasts Resist Apoptosis by Downregulating Caspase-3. Mech Ageing Dev. 2004;125(10-11):777-83. doi: 10.1016/j.mad.2004.07.007.
10. Neumaier T, Swenson J, Pham C, Polyzos A, Lo AT, Yang P, et al. Evidence for Formation of DNA Repair Centers and Dose-Response Nonlinearity in Human Cells. Proceedings of the National Academy of Sciences. 2011;109(2):443-8. doi: 10.1073/pnas.1117849108.
11. Belov O, Chigasova A, Pustovalova M, Osipov A, Eremin P, Vorobyeva N, et al. Dose-Dependent Shift in Relative Contribution of Homologous Recombination to DNA Repair after Low-LET Ionizing Radiation Exposure: Empirical Evidence and Numerical Simulation. Current Issues in Molecular Biology. 2023;45(9):7352-73. doi: 10.3390/cimb45090465.
12. Vaurijoux A, Voisin P, Freneau A, Barquinero JF, Gruel G. Transmission of Persistent Ionizing Radiation-Induced Foci Through Cell Division in Human Primary Cells. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis. 2017;797-799:15-25. doi: 10.1016/j.mrfmmm.2017.03.003.
13. Stewart RD. Two-Lesion Kinetic Model of Double-Strand Break Rejoining and Cell Killing. Radiation Research. 2001;156(4):365-78. doi: 10.1667/0033-7587(2001)156[0365:tlkmod]2.0.co;2.
14. Miller I, Min M, Yang C, Tian C, Gookin S, Carter D, et al. Ki67 is a Graded Rather than a Binary Marker of Proliferation versus Quiescence. Cell Rep. 2018;24(5):1105-12 e5. doi: 10.1016/j.celrep.2018.06.110.
15. Sobecki M, Mrouj K, Camasses A, Parisis N, Nicolas E, Lleres D, et al. The cell proliferation antigen Ki-67 organises heterochromatin. Elife. 2016;5:e13722. doi: 10.7554/eLife.13722.
16. Sobecki M, Mrouj K, Colinge J, Gerbe F, Jay P, Krasinska L, et al. Cell-Cycle Regulation Accounts for Variability in Ki-67 Expression Levels. Cancer Res. 2017;77(10):2722-34. doi: 10.1158/0008-5472.CAN-16-0707.
17. Maier AB, Westendorp RG, D VANH. Beta-Galactosidase Activity as a Biomarker of Replicative Senescence during the Course of Human Fibroblast Cultures. Annals of the New York Academy of Sciences. 2007;1100:323-32. doi: 10.1196/annals.1395.035.
18. Osipov A, Chigasova A, Yashkina E, Ignatov M, Fedotov Y, Molodtsova D, et al. Residual Foci of DNA Damage Response Proteins in Relation to Cellular Senescence and Autophagy in X-Ray Irradiated Fibroblasts. Cells. 2023;12(8). doi: 10.3390/cells12081209.
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The work was carried out with the support of the RSF (project No. 23-14-00078).
Contribution. Article was prepared with equal participation of the authors.
Article received: 20.01.2024. Accepted for publication: 27.02.2024.